Monograph Details
|
|
Cardiovascular System
> CHF and arrhythmias
|
|
ATACAND |
| Manufacturer |
|
AstraZeneca Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Angiotensin II receptor blocker. |
| Generic Name |
|
Candesartan cilexetil 4mg, 8mg, 16mg, 32mg; tabs. |
| Indications |
|
Heart failure (NYHA class II-IV and ejection fraction ≤40%), to reduce risk of death and hospitalization; alone or with an ACE inhibitor. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: Initially 4mg once daily; double daily dose at 2-week intervals as tolerated to target 32mg once daily. |
| Contraindications |
|
Pregnancy (Cat.D in 2nd and 3rd trimesters). |
| Precautions |
|
Correct hypovolemia before starting or monitor closely. Monitor BP, serum creatinine, and K+ during dose increases, then periodically. Severe renal impairment. Severe CHF. Renal artery stenosis. Elderly. Pregnancy (Cat.C in 1st trimester). Nursing mothers: not recommended. |
| Interactions |
|
Monitor lithium and for hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. |
| Adverse Reactions |
|
Back pain, dizziness, upper respiratory tract infection, pharyngitis, rhinitis, rhabdomyolysis (rare). |
| How Supplied |
Tabs 4mg, 8mg—30
16mg, 32mg—30, 90 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
